Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
第3相
実施中（募集終了）
NCT02486718
| 対象疾患 | Non-Small Cell Lung Cancer |
|---|
| 相 | 第3相 |
|---|
| スポンサー | Hoffmann-La Roche |
|---|
| ステータス | 実施中（募集終了） |
|---|
| 参加者数 | 1,280 名 |
|---|
| 介入（薬剤） | Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine |
|---|
| 開始日 | 2015年10月31日 |
|---|
| 完了日 | 2024年1月26日 |
|---|
| 結果公開日 | 2025年3月30日 |
|---|
概要
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Disease-Free Survival (DFS) in Intent-to-treat (ITT) Population
Up to 95 months · months
| Atezolizumab | 65.6 months |
|---|
| Best Supportive Care (BSC) | 47.8 months |
|---|
| p-value | 0.0683 |
|---|
| Hazard Ratio (HR) | 0.848 (95% CI 0.710–1.013) |
|---|
DFS in All Randomized Stage II-IIIA Population
Up to 95 months · months
| Atezolizumab | 57.4 months |
|---|
| Best Supportive Care (BSC) | 40.8 months |
|---|
| Hazard Ratio (HR) | 0.830 (95% CI 0.691–0.998) |
|---|
DFS in the Programmed Death-ligand 1 (PD-L1) SP263 ≥ 1% Tumor Cell (TC) Subpopulation Within the Stage II-IIIA Population
Up to 95 months · months
| Atezolizumab | 68.5 months |
|---|
| Best Supportive Care (BSC) | 37.3 months |
|---|
| Hazard Ratio (HR) | 0.704 (95% CI 0.545–0.910) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。